Abstract
Significant progress has been achieved in the treatment of acute lymphoblastic leukemia (ALL) by the introduction of modern chemotherapeutic strategies [1]. However, disease relapse following successful remission induction still poses a major clinical challenge. The quantity and kinetic behavior of residual leukemic cells remains largely enigmatic due to the limitation of most currently available techniques to identify less than 1%–5% neoplastic cells in the population being examined [2]. The use of double-color immunofluorescence has markedly improved the sensitivity with which persisting disease can be detected in distinct leukemias characterized by phenotypic features that are extremely rare or absent on normal hematopoietic counterparts [3]. More recently the development of polymerase chain reaction (PCR) strategies has opened a new era in the analysis of minimal residual disease by allowing the identification of neoplastic cells at a 10−4 to 10−6 level [4]. In the following we will summarize our experience with the application of PCR techniques in monitoring ALL patients during the course of the disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Champlin R, Gale RP (1989) Acute lymphoblastic leukemia: recent advantages in biology and therapy. Blood 73: 2051–2066
Hagenbeek A, Löwenberg B (eds) (1986) Minimal residual disease in acute leukemia. Nijhoff, Dordrecht
Campana D, Coustan-Smith E, Janossy G (1990) The immunologic detection of residual disease in acute leukemia. Blood 76: 163–171
Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA (1988) Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239: 487–491
Hansen-flagge TE, Yokota S, Bartram CR (1989) Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor ô chain sequences. Blood 74: 1762–1767
D’Auriol L, Maclntyre E, Galibert F, Sigaux F (1989) In vitro amplification of Teell y gene rearrangements: a new tool for the assessment of minimal residual disease in acute lymphoblastic leukemias. Leukemia 3: 155–158
Yamada M, Hudson S, Tournay O. Bitten-bender S, Shane SS, Lange B, Tsujimoto Y, Caton AJ, Rovera G (1989) Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using thirdcomplementarity-determining region (CDR-III) specific probes. Proc Natl Acad Sci USA 15. 86: 5123–5127
Yokota S, Hansen-Hagge TE, Bartram CR (1991) T-cell receptor S gene recombination in common acute lymphoblastic leukemia: preferential usage of VS, and frequent involvement of the Ja cluster. Blood 77: 141–148
Yokota S, Hansen-Hagge TE, Ludwig WD, Reiter A, Raghavachar A, Kleihauer E, Bartram CR (1991) The use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 77: 331–339
Campana D, Yokota S, Coustan-Smith E, Hansen-Hagge TE, Janossy G, Bartram CR (1990) The detection of residual acute lymphoblastic leukemia cells with immunologic methods and polymerase chain reaction: a comparative study. Leukemia 4: 609–614
Yamada M, Wasserman R, Lange B, Reichard BA, Womer RB, Rovera G (1990) Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment. N Engl J Med 323: 488–495
Macintyre EA, d’Auriol L, Duparc N, Leverger G, Galibert F, Sigaux F (1990) Use of oligonucleotide probes directed against Teell antigen receptor gamma delta variable(diversity)-joining junctional sequences as a general method for detecting minimal residual disease in acute lymphoblastic leukemias. J Clin Invest 86: 2125–2135
Raghavachar A,Thiel E, Bartram CR (1987) Analyses of phenotype and genotype in acute lymphoblastic leukemias at first presentation and in relapse. Blood 70: 1079–1083
Martens ACM, Schultz FW, Hagenbeek A (1987) Nonhomogenous distribution of leukemia in the bone marrow during minimal residual disease. Blood 70: 1073–1078
Kurzrock R, Gutterman JU,Talpaz M (1988) The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319: 990–998
Maurer J, Janssen JWG, Thiel E, van Den-deren J, Ludwig WD, Aydemir Ü, Heinze B, Fonatsch C, Harbott J, Reiter A, Riehm H, Hoelzer D, Bartram CR (1991) Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by polymerase chain reaction: frequency and clinical relevance. Lancet 337: 1055–1058
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Bartram, C.R., Yokota, S., Biondi, A., Janssen, J.W.G., Hansen-Hagge, T.E. (1992). Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia Patients by Polymerase Chain Reactions. In: Hiddemann, W., Büchner, T., Wörmann, B., Plunkett, W., Keating, M., Andreeff, M. (eds) Acute Leukemias. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 34. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76591-9_25
Download citation
DOI: https://doi.org/10.1007/978-3-642-76591-9_25
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-53949-0
Online ISBN: 978-3-642-76591-9
eBook Packages: Springer Book Archive